Monday, September 26, 2011

Quetiapine (Seroquel) and Atorvastatin (Liiptor) Sales volume will double post patent Expiry


Quetiapine (Seroquel) and Atorvastatin (Liiptor) Sales volume will double post patent Expiry and this will bode well for the generic and API companies prepared to participate in these opportunities.

Lipitor sales post patent expiry has always been a topic of debate. However with the announcement of data from SATURN trial, crestor failing to show superiority over lipitor on plaque reduction, there has been a consensus that Lipitor will atleast double to regain its market share, it had before the Zocor patent expiry (around 36%).
Indian Companies having stake in Lipitor OR Atorvastatin Generics / API
Ranbaxy
Zydus Cadila Healthcare
Cadila Pharmaceuticals
Ind-Swift Lab - Pure API
Biocon
Reddy
Torrent
Jubilant
Morepen - Purel API

Among the anti-pyschotic drugs, Seroquel has the best efficacy/safety profile among.  Seroquel has also recently been approved as an adjunctive therapy for treating depression and it is gaining market share in this therapy. Once the patent expires, Seroquel would take share from other aniti-psychotics - Zyprexa, Geodon, Abilify, to become the largest selling therapy in schizophrenia. While seroquel prescriptions will gain further traction to as an adjunctive therapy for depression. The prescriptions should atleast double from current levels.

Indian Companies having stake in Seroquel or  Quetiapine generics /  API
Ind-Swift laboratories - Pure API
Ranbaxy
Lupin
Jubilant
Divis - Pure API
Alembic
Torrent
Aurobindo
Cipla
Reddy's
Cadila
Dishman